A surrogate marker to monitor angiogenesis at last

被引:29
作者
Schneider, M [1 ]
Tjwa, M [1 ]
Carmeliet, P [1 ]
机构
[1] Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium
关键词
D O I
10.1016/j.ccr.2004.12.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The first angiogenesis inhibitor has recently been approved for cancer treatment. Nonetheless, optimizing the dose of novel angiogenesis inhibitors remains a formidable challenge-primarily because we lack reliable surrogate markers of tumor anglogenesis. In this issue, Shaked et al. provide evidence that the levels of circulating endothelial precursor cells (CEPs), which contribute to the formation of tumor vessels, are genetically predetermined and regulated by angiogenic factors, and reflect the antitumor efficacy of angiogenesis inhibitors. These findings highlight the potential usefulness of CEPs as a surrogate marker to monitor and adjust antiangiogenic therapy.
引用
收藏
页码:3 / 4
页数:2
相关论文
共 9 条
  • [1] Isolation of putative progenitor endothelial cells for angiogenesis
    Asahara, T
    Murohara, T
    Sullivan, A
    Silver, M
    vanderZee, R
    Li, T
    Witzenbichler, B
    Schatteman, G
    Isner, JM
    [J]. SCIENCE, 1997, 275 (5302) : 964 - 967
  • [2] Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
    Carmeliet, P
    Moons, L
    Luttun, A
    Vincenti, V
    Compernolle, V
    De Mol, M
    Wu, Y
    Bon, F
    Devy, L
    Beck, H
    Scholz, D
    Acker, T
    DiPalma, T
    Dewerchin, M
    Noel, A
    Stalmans, I
    Barra, A
    Blacher, S
    Vandendriessche, T
    Ponten, A
    Eriksson, U
    Plate, KH
    Foidart, JM
    Schaper, W
    Charnock-Jones, DS
    Hicklin, DJ
    Herbert, JM
    Collen, D
    Persico, MG
    [J]. NATURE MEDICINE, 2001, 7 (05) : 575 - 583
  • [3] Circulating endothelial progenitor cells, vascular function, and cardiovascular risk
    Hill, JM
    Zalos, G
    Halcox, JPJ
    Schenke, WH
    Waclawiw, MA
    Quyyumi, AA
    Finkel, T
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) : 593 - 600
  • [4] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz, H
    Fehrenbacher, L
    Novotny, W
    Cartwright, T
    Hainsworth, J
    Heim, W
    Berlin, J
    Baron, A
    Griffing, S
    Holmgren, E
    Ferrara, N
    Fyfe, G
    Rogers, B
    Ross, R
    Kabbinavar, F
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) : 2335 - 2342
  • [5] Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
    Jain, RK
    [J]. NATURE MEDICINE, 2001, 7 (09) : 987 - 989
  • [6] Imaging of angiogenesis: from microscope to clinic
    McDonald, DM
    Choyke, PL
    [J]. NATURE MEDICINE, 2003, 9 (06) : 713 - 725
  • [7] Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development
    Park, JW
    Kerbel, RS
    Kelloff, GJ
    Barrett, JC
    Chabner, BA
    Parkinson, DR
    Peck, J
    Ruddon, RW
    Sigman, CC
    Slamon, DJ
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (11) : 3885 - 3896
  • [8] Vascular and haematopoietic stem cells:: Novel targets for anti-angiogenesis therapy?
    Rafii, S
    Lyden, D
    Benezra, R
    Hattorï, K
    Heissig, B
    [J]. NATURE REVIEWS CANCER, 2002, 2 (11) : 826 - 835
  • [9] Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
    Willett, CG
    Boucher, Y
    di Tomaso, E
    Duda, DG
    Munn, LL
    Tong, RT
    Chung, DC
    Sahani, DV
    Kalva, SP
    Kozin, SV
    Mino, M
    Cohen, KS
    Scadden, DT
    Hartford, AC
    Fischman, AJ
    Clark, JW
    Ryan, DP
    Zhu, AX
    Blaszkowsky, LS
    Chen, HX
    Shellito, PC
    Lauwers, GY
    Jain, RK
    [J]. NATURE MEDICINE, 2004, 10 (02) : 145 - 147